vs
NAVIENT CORP（NAVI）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是NAVIENT CORP的1.5倍（$207.3M vs $137.0M），NAVIENT CORP净利率更高（-5.0% vs -62.0%，领先57.0%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -38.3%），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs -30.9%）
纳文特公司是一家总部位于美国特拉华州威尔明顿的金融服务企业，前身是学生贷款服务商。公司于2014年由学生贷款机构萨利美拆分而来，目前在美国各地设有办事处，共有约4500名员工，2018年时曾承接全美四分之一的学生贷款业务，2024年被禁止承接联邦学生贷款业务。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
NAVI vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $137.0M | $207.3M |
| 净利润 | $-6.0M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | -5.9% | -54.7% |
| 净利率 | -5.0% | -62.0% |
| 营收同比 | -38.3% | 25.9% |
| 净利润同比 | -125.0% | 3.5% |
| 每股收益（稀释后） | $-0.05 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $137.0M | $207.3M | ||
| Q3 25 | $161.0M | $159.9M | ||
| Q2 25 | $156.0M | $166.5M | ||
| Q1 25 | $156.0M | $139.3M | ||
| Q4 24 | $222.0M | $164.6M | ||
| Q3 24 | $396.0M | $139.5M | ||
| Q2 24 | $247.0M | $147.0M | ||
| Q1 24 | $287.0M | $108.8M |
| Q4 25 | $-6.0M | $-128.6M | ||
| Q3 25 | $-86.0M | $-180.4M | ||
| Q2 25 | $14.0M | $-115.0M | ||
| Q1 25 | $-2.0M | $-151.1M | ||
| Q4 24 | $24.0M | $-133.2M | ||
| Q3 24 | $-2.0M | $-133.5M | ||
| Q2 24 | $36.0M | $-131.6M | ||
| Q1 24 | $73.0M | $-170.7M |
| Q4 25 | -5.9% | -54.7% | ||
| Q3 25 | -72.7% | -106.9% | ||
| Q2 25 | 11.5% | -64.8% | ||
| Q1 25 | -3.2% | -102.6% | ||
| Q4 24 | 11.7% | -74.3% | ||
| Q3 24 | 3.0% | -94.6% | ||
| Q2 24 | 19.4% | -79.1% | ||
| Q1 24 | 30.7% | -151.9% |
| Q4 25 | -5.0% | -62.0% | ||
| Q3 25 | -53.4% | -112.8% | ||
| Q2 25 | 9.0% | -69.0% | ||
| Q1 25 | -1.3% | -108.5% | ||
| Q4 24 | 10.8% | -80.9% | ||
| Q3 24 | -0.5% | -95.7% | ||
| Q2 24 | 14.6% | -89.5% | ||
| Q1 24 | 25.4% | -156.8% |
| Q4 25 | $-0.05 | $-1.28 | ||
| Q3 25 | $-0.87 | $-1.81 | ||
| Q2 25 | $0.13 | $-1.17 | ||
| Q1 25 | $-0.02 | $-1.57 | ||
| Q4 24 | $0.24 | $-1.34 | ||
| Q3 24 | $-0.02 | $-1.40 | ||
| Q2 24 | $0.32 | $-1.52 | ||
| Q1 24 | $0.64 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $637.0M | $421.0M |
| 总债务越低越好 | $40.6B | — |
| 股东权益账面价值 | $2.4B | $-80.0M |
| 总资产 | $48.7B | $1.5B |
| 负债/权益比越低杠杆越低 | 16.94× | — |
8季度趋势，按日历期对齐
| Q4 25 | $637.0M | $421.0M | ||
| Q3 25 | $571.0M | $202.5M | ||
| Q2 25 | $712.0M | $176.3M | ||
| Q1 25 | $642.0M | $127.1M | ||
| Q4 24 | $722.0M | $174.0M | ||
| Q3 24 | $1.1B | $150.6M | ||
| Q2 24 | $1.1B | $480.7M | ||
| Q1 24 | $823.0M | $112.3M |
| Q4 25 | $40.6B | — | ||
| Q3 25 | $41.4B | — | ||
| Q2 25 | $42.3B | — | ||
| Q1 25 | $42.9B | — | ||
| Q4 24 | $43.2B | — | ||
| Q3 24 | $44.7B | — | ||
| Q2 24 | $47.5B | — | ||
| Q1 24 | $50.8B | — |
| Q4 25 | $2.4B | $-80.0M | ||
| Q3 25 | $2.4B | $9.2M | ||
| Q2 25 | $2.6B | $151.3M | ||
| Q1 25 | $2.6B | $144.2M | ||
| Q4 24 | $2.6B | $255.0M | ||
| Q3 24 | $2.7B | $346.8M | ||
| Q2 24 | $2.7B | $432.4M | ||
| Q1 24 | $2.8B | $140.3M |
| Q4 25 | $48.7B | $1.5B | ||
| Q3 25 | $49.3B | $1.2B | ||
| Q2 25 | $50.2B | $1.3B | ||
| Q1 25 | $51.0B | $1.3B | ||
| Q4 24 | $51.8B | $1.5B | ||
| Q3 24 | $53.4B | $1.5B | ||
| Q2 24 | $56.6B | $1.6B | ||
| Q1 24 | $59.0B | $1.3B |
| Q4 25 | 16.94× | — | ||
| Q3 25 | 16.98× | — | ||
| Q2 25 | 16.52× | — | ||
| Q1 25 | 16.56× | — | ||
| Q4 24 | 16.35× | — | ||
| Q3 24 | 16.59× | — | ||
| Q2 24 | 17.30× | — | ||
| Q1 24 | 18.38× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $441.0M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $441.0M | $-99.8M | ||
| Q3 25 | $70.0M | $-91.4M | ||
| Q2 25 | $126.0M | $-108.3M | ||
| Q1 25 | $71.0M | $-166.5M | ||
| Q4 24 | $459.0M | $-79.3M | ||
| Q3 24 | $-10.0M | $-67.0M | ||
| Q2 24 | $279.0M | $-77.0M | ||
| Q1 24 | $182.0M | $-190.7M |
| Q4 25 | — | $-100.8M | ||
| Q3 25 | — | $-92.7M | ||
| Q2 25 | — | $-110.7M | ||
| Q1 25 | — | $-167.8M | ||
| Q4 24 | — | $-79.5M | ||
| Q3 24 | — | $-68.6M | ||
| Q2 24 | — | $-79.0M | ||
| Q1 24 | — | $-193.9M |
| Q4 25 | — | -48.6% | ||
| Q3 25 | — | -58.0% | ||
| Q2 25 | — | -66.5% | ||
| Q1 25 | — | -120.5% | ||
| Q4 24 | — | -48.3% | ||
| Q3 24 | — | -49.2% | ||
| Q2 24 | — | -53.7% | ||
| Q1 24 | — | -178.2% |
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | — | 3.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 9.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 19.13× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 7.75× | — | ||
| Q1 24 | 2.49× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NAVI
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
